Advertisement
Advertisement
U.S. markets close in 5 hours 54 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8700+0.0398 (+4.79%)
As of 09:57AM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    BigPoppa
    The FDA's approval of Bristol-Myers' new psoriasis drug which is also a kinase inhibitor is good for Inhibikase I think.
  • B
    BigPoppa
    Closing over a 1.00 today!
    Bullish
  • M
    Mack
    Up 40% in 3 weeks. 🚀
    Bullish
  • B
    BobC
    This looks VERY promising:

    IkT-001Pro has shown to be potentially as much as five times safer than imatinib in non-human primates, blunting the severe gastrointestinal side effects of imatinib therapy that occur following oral administration. Removing these gastrointestinal side effects has the potential to significantly improve the number of patients that reach and sustain complete cytogenetic response in stable-phase chronic myelogenous leukemia (CML). We believe that removing these side effects will also improve patient adherence to daily therapy and improve patients' quality of life while on therapy.

    IkT-001Pro has received Orphan Drug Designation for stable-phase CML and will follow the development pathway for approval through the 505(b)(2) regulation. This pathway would allow us to rely, in part, on data in the public domain or the FDA’s prior conclusions regarding the safety and effectiveness of an approved compound.
  • R
    Rex
    The Lord give gives and The Lord taketh away
  • M
    Mack
    $XPEV conversation
    I’ve got a bunch of cash just waiting for the right time. The two at the top of my list are this and $IKT.
  • M
    Mack
    001Pro IND is very positive news. We should be at $5 already. Why? Because phase 3 data for Imatinib is already in the public record… all IKT must do is:
    1. Bioequivalence study
    2. Superiority study

    These take just a few months to complete. Then comes partnership to commercialize.
    Bullish
  • R
    Rex
    Creskin you are truly amazing 😁👍
  • B
    BobC
    Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the International Congress of Parkinson's Disease and Movement Disorders. The congress is being held in Madrid, Spain and virtually between September 15-18, 2022.

    https://mma.prnewswire.com/media/1441491/IKT_Logo_Logo.jpg
  • M
    Mack
    What is the market size for a safer, more effective version of Imatinib?

    Imatinib (Gleevec) market while under patent was up to $6B/y. As a generic, Imatinib still generates $1B/y.

    Dasatinib (Sprycel), for people with intolerance to Imatinib, generates $1.6B/y.

    Target market size: $2.6B to $7.6B.

    IKT has a patent on 001Pro until 2033.
    Bullish
  • B
    BobC
    Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
    Bullish
  • S
    Sarah
    I bought 10,000 shares about 6 months ago. I bought this for their PD drug. What's going on with 001Pro? We still on track with the PD drug?
  • M
    Mack
    Buy and hold! Super small float. In three years this will be worth 500x… market cap of $10B.
    Bullish
  • B
    Brent
    Let's hope Madrid turns into something real for the share price and not a pop and drop.
  • B
    BobC
    Got some additional positive news today... Time to buy more shares!
    Bullish
  • M
    Mack
    After bioequivalence and superiority studies are complete (in November) who might want to partner?

    Currently 25 different Pharma companies make, market, and distribute either Imatinib or Dasatinib worldwide. For anyone of them, partnership, in exchange for exclusivity is a no-brainer!
    Bullish
  • R
    Rex
    I’m now only 15% underwater on IKT didn’t time that buying very well but great promise awaits
  • T
    The Amazing Creskin
    Inhibikase is dosing. The 12-week clock has started for the first participants.
  • M
    Mack
    IND! 3 months to partnership and revenue!
  • M
    Mack
    Massive non-dilutive revenue coming in 2022. This is a game changer!
    Bullish
Advertisement
Advertisement